Arch Therapeutics

Arch Therapeutics' mission is to improve surgical and wound care outcomes through its innovative self-assembling peptide technology, which forms a protective barrier at the wound site. The company's key achievement is the U.S. commercial launch of its AC5 Advanced Wound System for exuding wounds. Its current strategy is focused on driving adoption and sales of AC5 while leveraging its core platform for potential future applications in hemostasis. As a publicly traded entity, Arch operates in the competitive but high-value medical device sector for bleeding control.

Proprietary self-assembling synthetic peptides that form a nanofibrous matrix upon contact with physiological fluids to control bleeding and manage exudate independently of the body's clotting cascade.

Arch competes in advanced wound care against giants like Smith & Nephew and 3M, and in surgical hemostasis against Johnson & Johnson (Ethicon) and Baxter. Its primary advantage is its novel, physiology-independent technology, but it faces challenges in commercial scale, market access, and competing with established sales forces and brands.